First author, year [ref] Number of participants (M-F) Age (y) Inclusion criteria Dietary supplement Duration (wk) Mean or median baseline HDL-C (mmol/L) Mean post-HDL-C (mmol/L) Δ change (within groups) ( value) MDΔ (between groups) ( value) Study design (level of evidence) Intervention Control Rondanelli, 2014 [47 ] 92 (41-51) Mild hypercholesterolaemia (5.4–7.0 mmol/L) LE: 0.5 g/diePatients: 46 PlaceboPatients: 46 8 I: C: NR I: +0.207 ( ) C: +0.005 ( = NS) +0.202 ( ) Randomized, double-blind, placebo-controlled trial (Level 2) Bundy, 2008 [48 ] 75 (27-48) 57.5 (SD NR) Age over 50 years and BMI range of 20–25 kg/m2 LE: 1.28 g/diePatients: 35 PlaceboPatients: 38 12 I: C: I: C: I: −0.01 ( = NS) C: +0.01 ( = NS) −0.02 ( = NR) Randomized, double-blind placebo-controlled trial (Level 2) Nazni, 2006 [49 ] 30 (NR-NR) 40 (SD NR) Diabetic type 2 with no insulin therapy LE: 6 g/diePatients: 15 PlaceboPatients: 15 12 I: C: I: C: I: 0.23 ( ) C: +0.01 ( = NS) 0.22 ( = NR) Placebo-controlled trial (Level 3) Rondanelli, 2013 [50 ] 55 (25-30) BMI from 25 to 35 kg/m2 with IFG (6.1–7.0 mmol/L), glycosylated haemoglobin < 7.0%, and no history of CVD FBE: 0.6 g/diePatients: 26 PlaceboPatients: 29 8 I: C: NR I: +0.00 ( = NS) C: −0.04 ( = NS) 0.04 ( = NS) Randomized, double-blind, placebo-controlled trial (Level 2) Englisch, 2000 [51 ] 143 (47-96) 51.9 (SD NR) Age between 18 and 70 years with TC > 7.3 mmol/L DE: 1.8 g/diePatients: 72 PlaceboPatients: 71 6 I: C: I: C: I: −0.04 ( = NR) C: +0.01 ( = NR) −0.05 ( = NS) Randomized, double-blind, placebo-controlled, multicentre clinical trial (Level 2)